Pomalidomide-amino-PEG5-NH2 hydrochloride is primarily used in the development of targeted cancer therapies. Its structure allows it to be conjugated with antibodies or other targeting molecules, enabling precise delivery to cancer cells. This compound is particularly valuable in the design of antibody-drug conjugates (ADCs), where it helps enhance the therapeutic efficacy while minimizing off-target effects. Additionally, it is utilized in research to study protein degradation pathways, especially in the context of proteolysis-targeting chimeras (PROTACs), which are emerging as a promising approach in drug discovery. The PEG5 linker improves solubility and stability, making it suitable for various biomedical applications.